704 related articles for article (PubMed ID: 28134289)
41. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
42. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
Zhou SJ; Liu FY; Zhang AH; Liang HF; Wang Y; Ma R; Jiang YH; Sun NF
Br J Cancer; 2017 Jul; 117(2):233-244. PubMed ID: 28588321
[TBL] [Abstract][Full Text] [Related]
44. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma.
Xiao H; Jiang N; Zhou B; Liu Q; Du C
Cancer Sci; 2015 Feb; 106(2):151-9. PubMed ID: 25495189
[TBL] [Abstract][Full Text] [Related]
45. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
46. [Changes of metastatic potential of residual hepatocellular carcinoma in nude mice after in vivo chemotherapy and the corresponding mechanisms].
Xiong W; Tang ZY; Ren ZG; Zhu XD; Liu L; Zhang W; Wang WQ
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):805-9. PubMed ID: 23291126
[TBL] [Abstract][Full Text] [Related]
47. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
48. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
49. Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells.
Gao Y; Li W; Liu R; Guo Q; Li J; Bao Y; Zheng H; Jiang S; Hua B
Oncol Rep; 2017 Aug; 38(2):1224-1232. PubMed ID: 28677802
[TBL] [Abstract][Full Text] [Related]
50. Post-transcription mediated Snail stabilization is involved in radiation exposure induced invasion and migration of hepatocarcinoma cells.
Dong L; Zhang X; Xiang W; Ni J; Zhou W; Li H
Biomed Pharmacother; 2018 Jul; 103():767-772. PubMed ID: 29684855
[TBL] [Abstract][Full Text] [Related]
51. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
52. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma.
Su Q; Fan M; Wang J; Ullah A; Ghauri MA; Dai B; Zhan Y; Zhang D; Zhang Y
Cell Death Dis; 2019 Dec; 10(12):939. PubMed ID: 31819036
[TBL] [Abstract][Full Text] [Related]
53. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma.
Meng J; Sun B; Zhao X; Zhang D; Zhao X; Gu Q; Dong X; Zhao N; Liu P; Liu Y
Mol Cancer Ther; 2014 Dec; 13(12):3107-22. PubMed ID: 25277383
[TBL] [Abstract][Full Text] [Related]
54. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
55. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
56. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
Kim JO; Kim KH; Song IS; Cheon KS; Kim OH; Lee SC; Lee SK; Kim SJ
Oncotarget; 2017 Jan; 8(2):2936-2948. PubMed ID: 27935857
[TBL] [Abstract][Full Text] [Related]
57. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.
Hou KZ; Fu ZQ; Gong H
World J Gastroenterol; 2015 Jan; 21(2):475-83. PubMed ID: 25593462
[TBL] [Abstract][Full Text] [Related]
58. RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition.
Song FN; Duan M; Liu LZ; Wang ZC; Shi JY; Yang LX; Zhou J; Fan J; Gao Q; Wang XY
PLoS One; 2014; 9(9):e108507. PubMed ID: 25268581
[TBL] [Abstract][Full Text] [Related]
59. The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma.
Ma CQ; Yang Y; Wang JM; Du GS; Shen Q; Liu Y; Zhang J; Hu JL; Zhu P; Qi WP; Qian YW; Fu Y
Cell Death Dis; 2014 Mar; 5(3):e1129. PubMed ID: 24651432
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-137 represses FBI-1 to inhibit proliferation and in vitro invasion and migration of hepatocellular carcinoma cells.
Zhu M; Li M; Wang T; Linghu E; Wu B
Tumour Biol; 2016 Oct; 37(10):13995-14008. PubMed ID: 27492460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
